Phase 3 Study Update of PA32540 for Prevention of Cardiovascular Disease - MPR
Links shared publicly online about this topic.
- 0total visits
Phase 3 Study Update of PA32540 for Prevention of Cardiovascular Disease - MPR
empr.com —
POZEN announced results from two pivotal Phase 3 clinical trials of PA32540, a coordinated-delivery tablet of immediate-release omeprazole (40mg) and delayed release aspirin (325mg) for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers.
View full resource at empr.com
Tags: Heart, Heart Disease, Disease and Condition, Phase 3 Clinical Trial, Clinical Trial, Cardiology, disease
Most Recently Shared on March 22, 2012 at 3:45 pm By:
Phase 3 Study Update of #PA32540 for Prevention of #Cardiovascular Disease #cardiology http://t.co/HOH1A1UC
Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease
medicalnewstoday.com — “Pervasis Therapeutics announced that the first cohort of patients has been fully enrolled in the Phase 1/2 clinical study of PVS-10200, an investigational new drug under development to prevent res” View full resource at medicalnewstoday.com
Most Recently Shared on June 23, 2010 at 12:37 pm By:
MNT Cardiovascular Health News
Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease http://mnt.to/3Ff9 #cardiovascular
Advertisement
